These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23210106)

  • 1. Prioritising CVD prevention therapy - absolute risk versus individual risk factors.
    Doust J; Sanders S; Shaw J; Glasziou P
    Aust Fam Physician; 2012 Oct; 41(10):805-9. PubMed ID: 23210106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cardiovascular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial.
    Vagholkar S; Zwar N; Jayasinghe UW; Denney-Wilson E; Patel A; Campbell T; Harris MF
    Am Heart J; 2014 Jan; 167(1):28-35. PubMed ID: 24332139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
    Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
    Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.
    Chen L; Rogers SL; Colagiuri S; Cadilhac DA; Mathew TH; Boyden AN; Peeters A; Magliano DJ; Shaw JE; Zimmet PZ; Tonkin AM;
    Med J Aust; 2008 Sep; 189(6):319-22. PubMed ID: 18803535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framing cardiovascular disease event risk prediction.
    Stone JA
    Can J Cardiol; 2011; 27(2):171-3. PubMed ID: 21459265
    [No Abstract]   [Full Text] [Related]  

  • 12. Ineffectiveness of lipid-lowering therapy in primary care.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Travier N; Yin D; Alemao E; de Pouvourville G
    Br J Clin Pharmacol; 2005 Apr; 59(4):456-63. PubMed ID: 15801941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
    Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
    Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general practice-based study examining the absolute risk of cardiovascular disease in treated hypertensive patients.
    Fahey TP; Peters TJ
    Br J Gen Pract; 1996 Nov; 46(412):655-9. PubMed ID: 8978111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies.
    Nelson MR; Doust JA
    Med J Aust; 2013 Jun; 198(11):606-10. PubMed ID: 23919708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.